Peripheral blood biomarkers predict viral rebound following antiretroviral therapy discontinuation in SIV-infected, early ART-treated rhesus macaques.
HIV-1
SIV
biomarker
rebound
reservoir
Journal
Cell reports. Medicine
ISSN: 2666-3791
Titre abrégé: Cell Rep Med
Pays: United States
ID NLM: 101766894
Informations de publication
Date de publication:
18 07 2023
18 07 2023
Historique:
received:
06
02
2023
revised:
16
05
2023
accepted:
21
06
2023
medline:
21
7
2023
pubmed:
20
7
2023
entrez:
19
7
2023
Statut:
ppublish
Résumé
The discovery of biomarkers that predict viral rebound after discontinuation of antiretroviral therapy (ART) would significantly contribute to the HIV cure field. We previously initiated ART in 20 rhesus macaques on days 0, 1, 2, and 3 following SIVmac251 infection. After 6 months, we discontinued ART and observed viral rebound in 9 of 20 animals, which provided an opportunity to define peripheral biomarkers on ART that predicted viral rebound following ART discontinuation. We show that interleukin-1 (IL-1), IL-6_JAK_STAT3, IL-10, transforming growth factor β (TGF-β), IL-22, and IL-23 signaling and activation of monocyte, macrophage, and antigen processing and presentation pathways during ART suppression correlated with viral rebound. These signatures were validated in a second cohort of macaques. Our data suggest that low levels of antigen and proinflammatory signaling during ART suppression correlate with the presence of a rebound-competent viral reservoir. Interventions that modulate these peripheral biomarkers may be promising candidates to evaluate as potential HIV-1 cure strategies.
Identifiants
pubmed: 37467721
pii: S2666-3791(23)00250-1
doi: 10.1016/j.xcrm.2023.101122
pmc: PMC10394255
pii:
doi:
Substances chimiques
Anti-Retroviral Agents
0
Biomarkers
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
101122Subventions
Organisme : NIAID NIH HHS
ID : UM1 AI164556
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI149670
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI129797
Pays : United States
Organisme : NIAID NIH HHS
ID : U19 AI128751
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI124377
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests The authors declare no competing interests.
Références
J Clin Invest. 2020 Jul 1;130(7):3381-3390
pubmed: 32609095
BMC Bioinformatics. 2019 Apr 16;20(1):189
pubmed: 30991955
J Infect Dis. 2011 Mar 15;203(6):780-90
pubmed: 21252259
Immunol Rev. 2013 Jul;254(1):326-42
pubmed: 23772629
Bioinformatics. 2011 Jun 15;27(12):1739-40
pubmed: 21546393
Front Immunol. 2019 Sep 20;10:2251
pubmed: 31616425
Nat Immunol. 2014 Feb;15(2):195-204
pubmed: 24336226
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Cell. 2022 Jan 20;185(2):266-282.e15
pubmed: 35026153
Bioinformatics. 2005 Nov 15;21(22):4148-54
pubmed: 16174683
NAR Genom Bioinform. 2020 Sep;2(3):lqaa078
pubmed: 33015620
Nature. 2014 Aug 7;512(7512):74-7
pubmed: 25042999
Open Forum Infect Dis. 2015 Jan 13;2(1):ofu117
pubmed: 25884005
Nat Commun. 2018 Dec 21;9(1):5429
pubmed: 30575753
J Virol. 2002 Jan;76(2):707-16
pubmed: 11752161
Trends Immunol. 2017 Jul;38(7):457-458
pubmed: 28511815
AIDS. 2016 Jan 28;30(3):343-53
pubmed: 26588174
PLoS Comput Biol. 2017 Nov 3;13(11):e1005752
pubmed: 29099853
Cell Syst. 2015 Dec 23;1(6):417-425
pubmed: 26771021
Immunity. 2018 May 15;48(5):872-895
pubmed: 29768175
Nat Commun. 2021 Jun 29;12(1):3922
pubmed: 34188039
Genome Med. 2012 Mar 29;4(3):28
pubmed: 22458606
Nat Commun. 2015 Oct 09;6:8495
pubmed: 26449164